Objective SLE is a heterogeneous systemic autoimmune disease with diverse clinical manifestations. We aimed to identify ...
The following transcript is automatically generated and may contain typos or misspellings. Please listen to the episode for the most accurate language. Dr. Susan Manzi 0:00 Hello everyone. I'm Dr.
Objective Psychological comorbidities are common in adolescents with SLE. Incorporating structured mental-health screening ...
A Phase II study was subsequently performed by the LBSL02/99 group, which enrolled 449 patients who met American College of Rheumatology (ACR) diagnostic criteria for SLE, had active SLE disease and ...
Our most recent episode of The Expert Series podcast “Your Lupus Treatment Roadmap: Understanding the New Guidelines and What They Mean for You” explores the newly released SLE treatment guidelines ...
The study is aimed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), preliminary efficacy and biomarkers of orelabrutinib in patients with mild to moderate SLE who ...
Given the shortcomings of proteinuria alone for lupus nephritis prognosis, a team is evaluating the Treatment Response Measure for SLE (TRM-SLE), a novel multi-domain clinical outcome assessment tool.
EXTON, PA, June 13, 2024 (GLOBE NEWSWIRE) -- Since 2021, the treatment options for systemic lupus erythematosus (SLE) and lupus nephritis (LN) have expanded with the approval of AstraZeneca’s Saphnelo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results